// App-Quantinova.ai

P-55 : GASTHER2: Efficacy of adding trastuzumab to standard chemotherapy in patients with advanced HER2-negative gastric cancer and HER2-positive expression in circulating tumor cells

Researchers

Presenter

  • R. Riechelmann

Principal Investigators

  • M. Donadio

  • V. Jesus

  • T. Felismino

  • C. Mello

  • V. Souza e Silva

  • M. Barros e Silva

  • M. Camandaroba

  • N. Rodrigues

  • A. Dettino

  • L. Chinen

Medical Centers

  • A.C. Camargo Cancer Center, Sao Paulo, Brazil

Locations

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

  • Oxaliplatin, 5-fluorouracil and folic acid

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved